索拉非尼用于肝细胞癌的治疗。

Sorafenib in hepatocellular carcinoma.

作者信息

Josephs Debra H, Ross Paul J

机构信息

ST3 in Medical Oncology, King's College Hospital and Guy's and St Thomas' Hospital, London.

出版信息

Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669.

DOI:10.12968/hmed.2010.71.8.77669

PMID:20852487

Abstract

Sorafenib, a small molecule multikinase inhibitor, is the standard of care in the USA and Europe for the treatment of advanced hepatocellular carcinoma. This article reviews its development from the basis of molecular hepatocarcinogenesis to phase III trials and discusses the future for sorafenib in hepatocellular carcinoma.

摘要

索拉非尼是一种小分子多激酶抑制剂，在美国和欧洲是治疗晚期肝细胞癌的标准疗法。本文回顾了其从分子肝癌发生基础到III期试验的发展历程，并探讨了索拉非尼在肝细胞癌治疗中的未来前景。